Indiplon: the development of a new hypnotic

被引:35
作者
Neubauer, DN [1 ]
机构
[1] Johns Hopkins, Bayvie Med Ctr, Baltimore, MD 21224 USA
关键词
alpha(1); selective; GABA(A) receptors; hypnotic; indiplon; insomnia; modified release; nonbenzodiazepine; sleep disorders;
D O I
10.1517/13543784.14.10.1269
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Indiplon is a short-acting hypnotic that is currently being developed as a treatment for insomnia by Neurocrine Biosciences and Pfizer, and is expected to be marketed in mid-2006. It is a high-affinity allosteric potentiator of GABA(A) responses that demonstrates preference for cc, subunit-containing GABA(A) receptors. Indiplon will be an addition to the general category of newer-generation hypnotics that now includes zaleplon, zolpidem, zopiclone and eszopidone. Clinical trials were carried out with an immediate-release capsule and a modified-release tablet and demonstrate very positive efficacy and safety profiles. The major challenge will be developing a commercial success in the crowded insomnia treatment marketplace.
引用
收藏
页码:1269 / 1276
页数:8
相关论文
共 27 条
[1]
*AD INT LTD, 2002, DRUGS R D, V3, P197
[2]
Berkowitz DW, 2003, SLEEP, V26, pA81
[3]
Cohn M, 2004, SLEEP, V27, P261
[4]
Fisher D, 2002, DRUG METAB REV, V34, P171
[5]
EPIDEMIOLOGIC-STUDY OF SLEEP DISTURBANCES AND PSYCHIATRIC-DISORDERS - AN OPPORTUNITY FOR PREVENTION [J].
FORD, DE ;
KAMEROW, DB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (11) :1479-1484
[6]
In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic [J].
Foster, AC ;
Pelleymounter, MA ;
Cullen, MJ ;
Lewis, D ;
Joppa, M ;
Chen, TK ;
Bozigian, HP ;
Gross, RS ;
Gogas, KR .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (02) :547-559
[7]
Garber M, 2004, SLEEP, V27, P260
[8]
Hull S, 2004, SLEEP, V27, P261
[9]
Jochelson P, 2004, SLEEP, V27, P262
[10]
Jochelson P, 2003, SLEEP, V26, pA85